• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
Trump Planning for US Rollout of Coronavirus Vaccine Falling Short, Officials Warn

NIH Cautions There Is ‘Insufficient Data’ To Show ‘Efficacy and Safety’ of Trump-Touted COVID-19 Treatment

September 1, 2020
EXCLUSIVE: John Thune Shares His ‘Big, Beautiful’ GOP Sales Pitch For The Midterms

EXCLUSIVE: John Thune Shares His ‘Big, Beautiful’ GOP Sales Pitch For The Midterms

July 28, 2025
Robo-Bunnies Unleashed In Florida Everglades To Hunt Burmese Pythons

Robo-Bunnies Unleashed In Florida Everglades To Hunt Burmese Pythons

July 28, 2025
Political Violence Surging Under Trump Isn’t Exactly ‘Far-Right’ After All

Political Violence Surging Under Trump Isn’t Exactly ‘Far-Right’ After All

July 27, 2025
DAVID BLACKMON: Zeldin, Trump, Prepare Assault On EPA Endangerment Finding

DAVID BLACKMON: Zeldin, Trump, Prepare Assault On EPA Endangerment Finding

July 27, 2025
EXCLUSIVE: GOP Rep Touts How Alaska Is Key To Unleashing American Energy Dominance

EXCLUSIVE: GOP Rep Touts How Alaska Is Key To Unleashing American Energy Dominance

July 27, 2025
STEVE MILLOY: Big Beautiful Bill Already Paying Big Beautiful Benefits

STEVE MILLOY: Big Beautiful Bill Already Paying Big Beautiful Benefits

July 27, 2025
George Santos Reports to New Jersey Prison

George Santos Reports to New Jersey Prison

July 27, 2025
MICHELE STEEB: A New Chapter For America’s Homeless: Structure, Recovery, And Hope

MICHELE STEEB: A New Chapter For America’s Homeless: Structure, Recovery, And Hope

July 26, 2025
JAMES CARTER: America’s Capex Comeback

JAMES CARTER: America’s Capex Comeback

July 26, 2025
NEWT GINGRICH: Trump Boom Or Democrat Gloom

NEWT GINGRICH: Trump Boom Or Democrat Gloom

July 26, 2025
JOSH HAMMER: Grading The Second Trump Presidency, Six Months In

JOSH HAMMER: Grading The Second Trump Presidency, Six Months In

July 26, 2025
Leftist Outrage Erupts At California Plan To Stop Paying Criminal Illegals’ Legal Bills

Leftist Outrage Erupts At California Plan To Stop Paying Criminal Illegals’ Legal Bills

July 26, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Monday, July 28, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home IJR

NIH Cautions There Is ‘Insufficient Data’ To Show ‘Efficacy and Safety’ of Trump-Touted COVID-19 Treatment

by Bradley Cortright
September 1, 2020 at 5:56 pm
in IJR
235 17
1
Trump Planning for US Rollout of Coronavirus Vaccine Falling Short, Officials Warn

FILE PHOTO: U.S. President Donald Trump delivers a speech during a tour of the Fujifilm Diosynth Biotechnologies' Innovation Center, a pharmaceutical manufacturing plant where components for a potential coronavirus disease (COVID-19) vaccine candidate are being developed, in Morrrisville, North Carolina, U.S., July 27, 2020. REUTERS/Carlos Barria/File Photo

491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

President Donald Trump is optimistic that convalescent plasma will be a game-changer in the fight against COVID-19.

On August 23, the Food and Drug Administration (FDA) announced it had granted an Emergency Use Authorization (EUA) for convalescent plasma, as IJR reported.

However, the National Institutes of Health (NIH) released a statement on findings compiled by The COVID-19 Treatment Guidelines Panel regarding the treatment.

“There are currently no data from well-controlled, adequately powered randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for the treatment of COVID-19,” the panel found.

“The FDA analysis of data on a subset of hospitalized patients from the Mayo Clinic’s Expanded Access Program (EAP) compared outcomes in patients who received convalescent plasma with high titers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies to outcomes in patients who received plasma with low titers and found no difference in 7-day survival overall.”

“Among patients who were not intubated, 11% of those who received convalescent plasma with high antibody titers died within 7 days of transfusion compared with 14% of those who received convalescent plasma with low antibody titers. Among those who were intubated, there was no difference in 7-day survival,” the statement added.

The NIH said that “data suggest that convalescent plasma with high antibody titers may be beneficial in nonintubated patients.” 

However, it cautioned that “uncertainty remains about the efficacy and safety of convalescent plasma due to the lack of a randomized control group and possible confounding in the Mayo Clinic’s EAP.”

“Based on the available evidence, the Panel has determined the following,” the statement continued. “There are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19.”

Additionally, the panel said that “serious adverse” reactions to convalescent plasma are “infrequent and consistent with the risks associated with plasma infusions for other indications.”

However, the panel did not examine the “long-term risks” of using convalescent plasma to treat COVID-19 or whether it could actually hurt a person’s immune response to the virus and make them “more susceptible to reinfection.”

“Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19,” the panel said.

Finally, the panel said “well-controlled, adequately powered randomized trials” are necessary to determine if convalescent plasma is effective.

Last week Trump announced that the FDA has issued the (EUA) and called it a “powerful therapy that transfuses very, very strong antibodies from the blood of recovered patients to help treat patients battling a current infection.”

However, officials at the FDA have now been accused of exaggerating the effectiveness of convalescent plasma, as IJR reported.

The New York Times reports that the EUA is now on hold as researchers conduct more tests to study the effectiveness and safety of the treatment. 

Share196Tweet123
Bradley Cortright

Bradley Cortright

IJR, Senior Writer He's written for Independent Journal Review since 2019.

Advertisements

Top Stories June 10th
Top Stories June 7th
Top Stories June 6th
Top Stories June 3rd
Top Stories May 30th
Top Stories May 29th
Top Stories May 24th
Top Stories May 23rd
Top Stories May 21st
Top Stories May 17th

Join Over 6M Subscribers

We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





IJR

    Copyright © 2024 IJR

Trusted Voices On All Sides

  • About Us
  • GDPR Privacy Policy
  • Terms of Service
  • Editorial Standards & Corrections Policy
  • Subscribe to IJR

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls

    Copyright © 2024 IJR

Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th